JAK2 and anemia (phenotype): Although combined Jak1 and Jak2 inhibitors appear to be effective in reducing spleen size and treating systemic symptoms in patients with primary MF and secondary MF, they appear to cause significant hematological toxicity, particularly worsening of anemia in around a quarter to a third of patients treated [12].